Organogenesis to Sponsor Jan. 30 Webinar, “Chronic Wounds and Biofilms: Advancing Assessment and Treatment,” Featuring Dr. Gregory Schultz
Webinar attendees will review the latest research on the prevalence of biofilms in chronic skin wounds and the underlying mechanisms of biofilm in wounds which inhibit healing. The webinar will also address the concept of Biofilm-Based Wound Care and the STEP-DOWN-THEN-STEP-UP approach for effective therapies in treating chronic wounds.
An important voice in the field of biotechnology and regenerative medicine, Dr. Schultz is a former president of the
“As a company committed to promoting evidence-based care,
For event details, including registration information, please visit the WoundSource event registration page.
The Company may make forward-looking statements in this report within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as “will,” “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” “extend,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward looking statements. Although they may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Press and Media Inquiries: Press Inquiries:
Angelyn Lowe Organogenesis Inc.email@example.com 781-774-9364 Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com 443-213-0500
Source: Organogenesis Holdings Inc.